XiaoMi-AI文件搜索系统
World File Search Systemdemonstrated
tezspire®（Tezepelumab-ekko） - 商业医疗福利药物政策
For continuation of therapy , all of the following: o Documentation of a positive clinical response as demonstrated by at least one of the following: Reduction in the frequency of exacerbations Decreased utilization of rescue medications Increase in percent predicted FEV1 from pretreatment baseline Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)和O与含ICS的维护药物结合使用； and o Patient is not receiving Tezspire in combination with any of the following: Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab), Nucala (mepolizumab] Anti-IgE therapy [e.g., Xolair (omalizumab)] Anti-interleukin 4 therapy [e.g., Dupixent （dupilumab）]和o tezspire剂量是根据美国食品和药物批准的标签； o重新授权的标签将不超过12个月的代码，以下是仅提供参考目的的程序和/或诊断代码的列表在本策略中列出代码并不意味着代码所描述的服务是涵盖或未覆盖的健康服务。卫生服务的福利覆盖范围由成员特定的福利计划文件和可能需要特定服务覆盖的适用法律确定。纳入代码并不意味着要偿还或保证索赔付款的任何权利。其他政策和准则可能适用。
loncastuximab tesirine在复发/难治性弥漫性大B ...
疗法。Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer, demonstrated single-agent antitumor activity in the pivotal phase II LOTIS-2 study in heavily pretreated patients with R/R DLBCL.在这里，我们提出了对所有患者和完全反应的患者（CR）的lotis-2进行更新的EFFI CACY和安全性分析，包括无事件（无疾病或死亡）≥1岁的CR的患者，距离周期1年，治疗第1天，≥2岁。lonca每3周一次服用每3周（2个周期为0.15 mg/kg；随后的周期为0.075 mg/kg）。截至最终数据截止（2022年9月15日；中值随访：7.8个月[范围，0.3-42.6]），145（48.3％）中的70名患者达到了总体反应。36例（24.8％）患者获得了CR，其中16（44％）和11（31％）分别为≥1岁和≥2岁。在全面治疗的人群中，中位总生存期为9.5个月；无进展的中位生存期为4.9个月。未达到CR，中值总生存期和无进展生存期的患者，总体24个月，无进展的生存率为68.2％（95％CI：50.0-81.0）和72.5％（95％CI：48.2-86.8），重新分配。未检测到新的安全问题。标识符：NCT03589469）。随着额外的随访，Lonca继续证明CR患者具有可管理的安全性和耐受性的持久，长期的反应（临床审判政府。
乙酰胆碱酯酶抑制活性和红槟榔叶（Piper crocatum ruiz \＆amp \; pav）的植物化学筛选为抗痴呆剂
摘要。阿尔茨海默氏病（AD）是一种神经退行性疾病，导致逐步认知的恶化。使用乙酰胆碱酯酶抑制剂的AD治疗方法旨在通过提高突触神经元中的乙酰胆碱水平来提高认知功能。Piper Crocatum Rui＆Pav具有抗氧化和抗炎特性，这表明其减轻AD症状的潜力。这项研究旨在研究体外乙酰胆碱酯酶（ACHE）的抑制活性，并鉴定红槟榔叶的馏分中存在的活性化合物。这项研究的方法是Ellman的比色方法和液相色谱 - 质谱法（LC-MS）。The red betel leaf fractions demonstrated effective AChE inhibition, as reflected by their IC 50 values: 11.0965 µg/ml (ethanol extract), 16.7908 µg/ml (ethyl acetate fraction), 23.7390 µg/ml (n- hexane fraction), and 41.0044 µg/ml (water fraction).通过LC-MS分析了最低IC 50值的乙醇提取物。结果显示了200种活性化合物，其中28种浓度超过0.5％。主要活性化合物包括类固醇，多酚，生物碱，酚类，维生素和羧酸。总而言之，红槟榔叶的乙醇提取物作为ACHE抑制剂具有有希望的潜力，这表明其用作治疗剂，以增强阿尔茨海默氏病患者的认知功能。
报销建议
来自两个随机，双掩盖的，安慰剂对照的III期试验（聚光灯和光芒）的证据表明，Zolbetuximab添加到氟吡啶胺 - 和铂型化疗（MFOLFOX6或CAPOX）中，用于对局部先进的不可脱位或转移的成年患者的含量为flofofox6或capox） CLDN18.2阳性，从而增加了临床益处。Spotlight试验（n = 565）表明，Zolbetuximab在MFOLFOX6组合中的治疗导致统计学意义和临床上有意义的总体生存率（OS;危险比[HR] = 0.784; 95％置信区间; 95％置信区间[CI]，0.644至0.644至0.954; P = 0.0075和Procesporive = 0.0075 = rsessive-freessive-freessive-freessive-freeversion-freeversiefeive（hr = rsessive-freeversie-freeverione-freeverione-freeverione free（hr）; 95％CI，0.598至0.942; P = 0.0066）与安慰剂与MFOLFOX6相比。The GLOW trial (N = 507) similarly demonstrated that treatment with zolbetuximab in combination with CAPOX resulted in statistically significant and clinically important meaningful improvements in OS (HR = 0.763; 95% CI, 0.622 to 0.936; P = 0.0047) and PFS (HR = 0.687; 95% CI, 0.544 to 0.866; P = 0.0007),与安慰剂与Capox结合使用相比。在关键试验中，与单独的化学疗法相比，用Zolbetuximab与化学疗法结合使用的化学疗法治疗与恶心，呕吐和输注相关反应（IRR）的风险增加有关。但是，PERC与临床专家一致，这些不良事件（AES）在临床实践中可能是可以管理的。
Amtco，一种研究药物的新型trans-环环烯衍生物 -
单击化学是指与高热力学力量快速完成的反应，以高收率产生单个产品。4通过使用可点击部分进行功能化，从药物中得出的单击探针通过单击探针和相关疾病模型中选择的记者之间的选择性反应实现结合。In previous work, we demonstrated that this strategy can be used to identify drug targets and off-targets, visualise the cellular localization of the probe and measure target engagement of non-derivatised drug compounds.5 In the same study, different click reactions were compared and the inverse electron demand Diels Alder (IEDDA) reaction between a trans-cyclooctene (TCO) and a tetrazine was identified as the most efficient.在我们的点击探针策略中，IEDDA反应的出色性能归因于其无与伦比的动力学。6TCO与四嗪的选择性和高反应性，结合其在水溶液中的延长稳定性，使其成为非常有吸引力的单击部分。尽管如此，TCO是一个疏水群。连接到药物时，它可能会影响点击探针的物理化学特性以及药物的药理特性。在这种情况下，几个研究小组已经做出了相当大的努力，以开发出具有疏水性降低的新的跨环烯衍生物（例如oxotco）7或更快的动力学（例如STCO，DTCO）.8,9
Cadth报销建议
One phase I/II, single-arm, open-label trial (MajesTEC-1) demonstrated that treatment with teclistamab may result in benefits in clinical response rates, overall survival (OS), and progression-free survival (PFS) for adult patients with relapsed or refractory MM (MM) who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti- CD38抗体。在此大量预处理的人群中，总体响应率（ORR）为63.0％（95％置信区间[CI]，55.2％至70.4％），该人口符合预先指定的主要终点|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| ||||| ||||| || ||| ||| || |||||||| ||||，完全反应或更好的响应率为45.5％（95％CI，37.7％至53.4％），这被临床专家认为在临床上有意义。尽管由于Majestec-1试验的单臂设计而与不确定性相关，但PERC认为OS和PFS结果有望。中位随访时间为22.8个月后，中位OS为21.9个月（95％CI，15.1至NE月），||||||||||| || |||||||||||| ||| ||||| ||| ||| ||||| || ||||||。中值PFS为11.3个月（95％CI，8.8至16.4个月），||||||||| ||| |||||||||||| ||| ||||| ||| ||| ||||| || ||||||。此外，尽管通过方法上的局限性，间接治疗比较的结果不确定性，但在评估的结果中，有利于teclistamab而不是现实世界医生的选择疗法的效果方向保持一致，包括临床反应，OS和PFS。Teclistamab治疗与可管理的毒性特征有关。
Cadth报销建议
一阶段III，双盲，安慰剂对照试验（敏捷; n = 146）表明，ivosidenib与氮杂丁丁（ivosidenib + Azacitidine）结合使用，从而增加了与IDH1 R132突变的新诊断为AML的成年患者，从而使成人患者与非强化化学相关化，从而增加了临床益处。The AGILE trial demonstrated that ivosidenib + azacitidine, when compared with placebo + azacitidine, resulted in statistically significant and clinically meaningful improvements in event-free survival (EFS) (hazard ratio [HR] = 0.33; 95% confidence interval [CI]: 0.16 to 0.69; P = 0.0011) and overall survival (OS) (HR = 0.44; 95％CI：0.27至0.73; p = 0.0005）在中间的随访时间。2年中位随访时间为28.6个月的OS率为53.1％（95％CI：|||| || |||||）和17.4％（95％CI：||| || || ||||）分别为ivosidenib + Azacitidine和chartbo + Azacitidine和Azacitidine群。PERC认为，与安慰剂 +阿扎西替丁相比，伊沃西二尼 +偶氮丁胺的安全性是可管理的，治疗伴随不良事件（TEAES）和3级茶水的发生率相似。PERC讨论了通过Ivosidenib治疗的QT延长和分化综合征的风险，并指出需要进行足够的监测和潜在剂量调整。
第1页，共2页环境部和...
1。在利益相关者参与和申诉/投诉处理方面表现出长达4年的工作经验； 2。在确定环境问题和监测发展方面具有范围练习方面的工作经验； 3。展示了管理信息流，寻求澄清并提供建议和回应以确保迅速解决问题的工作经验； 4。在解决/回应询问和投诉方面表现出工作经验，并在可能的情况下提供解决方案，或将其重定向到相关领域；和5。对相关环境行为和随后的立法的实际理解和知识。
对机器人技术的认识、态度和知识......
The aim of this study was to assess the awareness, attitude, and knowledge of Robotic technologies used in neurorehabilitation among Physiotherapy interns and Professionals across Maharashtra. A cross-sectional study was conducted in tertiary care hospitals and colleges in Maharashtra, India, using a self-made questionnaire. The results showed that 63% of the individuals are moderately aware, 67% have a positive outlook on the implementation of such advances but only 7.5% have accurate knowledge of the technology and its uses. Most of the participants also believe that Robotic Rehabilitation can be very time effective and reduce the load of the therapist as well as play a very important role in aiding neuroplasticity after rehabilitation. The study demonstrated that a higher degree of understanding and a more positive attitude regarding the application of Robotic Rehabilitation follow from heightened awareness of this field. Enhanced training programs, better integration of technology into rehabilitation practices, addressing time constraints and workload prioritization, and most importantly, overcoming economic barriers will ensure the effective implementation of Robotic therapies for the benefit of the patient and society as a whole. This will revolutionize the field of Physiotherapy and rehabilitation, offering new avenues for improving treatment outcomes and advances in clinical practice. The study concluded that, it is important to generate or enhance awareness towards the most-advancing fields and the uses of Robotic technology in neurological conditions in clinical practice which empowers Physiotherapy to adapt to the changing landscape of healthcare and deliver high-quality, patient-centered care. Keywords: Advanced Technology, Artificial Intelligence, Neurorehabilitation, Robotic Physiotherapy, Robotic Rehabilitation, Robotic Technology (RT) ________________________________________________________________________________________________________
综述探讨锂在缺血性中风中的神经保护作用：文献综述
缺血性中风是死亡和残疾的最重要临床原因之一，煽动神经元变性，死亡和各种后遗症。尽管标准治疗（例如静脉溶栓和血管内血栓切除术）证明有效，但它们会受到限制。因此，迫切需要开发能够改善神经系统功能结果的神经保护剂。Numerous preclinical studies have demonstrated that lithium can act in multiple molecular pathways, including glycogen synthase kinase 3(GSK-3), the Wnt signaling pathway, the mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated kinase (ERK) signaling pathway, brain-derived neurotrophic factor (BDNF), mammalian target of雷帕霉素（MTOR）和谷氨酸受体。通过这些途径，锂已被证明会影响炎症，自噬，凋亡，铁凋亡，兴奋性毒性和其他病理过程，从而改善了由缺血性中风引起的中枢神经系统（CNS）损害。尽管有这些有希望的临床前发现，但探索锂功效的临床试验数量仍然有限。必须进行其他试验，以彻底确定锂在临床环境中的有效性和安全性。本综述描述了在缺血性中风的背景下锂神经保护能力的基础的机制。它阐明了这些机制之间的复杂相互作用，并阐明了线粒体功能障碍和炎症标志物在缺血性中风的病理生理学中的参与。此外，该评论还提供了未来研究的指示，从而促进了对锂的潜在治疗效用的理解，并为其临床应用建立了理论基础。